Harmony Clinical Research, Inc.

North Miami Beach, Florida 33162

1 studies enrolling now · 13 studies all time

What they study most

Anhedonia, Atopic Dermatitis, Aura, Cardiovascular Disease, Chronic Disease, Depressive Disorder, Major, Lower Respiratory Tract Disease, Major Depressive Disorder, Migraine, Migraine With or Without Aura, Nausea, Pain

Studies at this site

• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder — Recruiting now
• An Open-Label Study of Azetukalner in Major Depressive Disorder — Enrolling by invitation
• A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure — Stopped early
• CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) — Running, not enrolling
• A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older — Completed
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia — Completed
• A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy — Stopped early
• A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis — Completed
• A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain — Completed
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c — Stopped early
• Conversion to Embeda With Rescue Trial — Stopped early